(Q52888818)

9 May 2018

title

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. (English)

1 reference

9 May 2018

author name string

Alexander Nast

1

1 reference

9 May 2018

Wolf-Henning Boehncke

2

1 reference

9 May 2018

Ulrich Mrowietz

3

1 reference

9 May 2018

Hans-Michael Ockenfels

4

1 reference

9 May 2018

Sandra Philipp

5

1 reference

9 May 2018

Kristian Reich

6

1 reference

9 May 2018

Thomas Rosenbach

7

1 reference

9 May 2018

Adel Sammain

8

1 reference

9 May 2018

Martin Schlaeger

9

1 reference

9 May 2018

Michael Sebastian

10

1 reference

9 May 2018

Wolfram Sterry

11

1 reference

9 May 2018

Volker Streit

12

1 reference

9 May 2018

Matthias Augustin

13

1 reference

9 May 2018

Ricardo Erdmann

14

1 reference

9 May 2018

Joachim Klaus

15

1 reference

9 May 2018

Joachim Koza

16

1 reference

9 May 2018

Siegrid Muller

17

1 reference

9 May 2018

Hans-Dieter Orzechowski

18

1 reference

9 May 2018

Stefanie Rosumeck

19

1 reference

9 May 2018

Gerhard Schmid-Ott

20

1 reference

9 May 2018

Tobias Weberschock

21

1 reference

9 May 2018

Berthold Rzany

22

1 reference

9 May 2018

Deutsche Dermatologische Gesellschaft (DDG)

23

1 reference

9 May 2018

Berufsverband Deutscher Dermatologen (BVDD)

24

1 reference

9 May 2018

publication date

1 March 2012

1 reference

9 May 2018

published in

JDDG

1 reference

9 May 2018

volume

10 Suppl 2

1 reference

9 May 2018

page(s)

S1-95

1 reference

9 May 2018

Psoriasis causes as much disability as other major medical diseases

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Objective assessment of compliance with psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Adherence to treatment in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Economic considerations in psoriasis management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Topical preparations for the treatment of psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A classification of psoriasis vulgaris according to phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The risk of mortality in patients with psoriasis: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Psoriasis: a possible risk factor for development of coronary artery calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Epidemiology and comorbidity of psoriasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The role of salicylic acid in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Tacrolimus ointment improves psoriasis in a microplaque assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A novelliposomal formulation of dithranol for psoriasis: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Microcirculatory modifications of psoriatic lesions during topical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Betamethasone valerate foam for treatment of nonscalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Comparison of Hypothalamus-Pituitary-Adrenal Axis Suppression From Superpotent Topical Steroids by Standard Endocrine Function Testing and Gas Chromatographic Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intra-individual pre/post comparison design".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Laser treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Medium-dose 308-nm excimer laser for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Tazarotene plus UVB phototherapy in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The mechanisms of action of cyclosporin A in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Fumaric acid esters in the treatment of psoriasis: an Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Review and expert opinion on prevention and treatment of infliximab-related infusion reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Methotrexate for psoriasis. A new therapeutic schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Side-effect profile of acitretin therapy in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy of Acitretin and Commercial Tanning Bed Therapy for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Acitretin in combination with UVB or PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Balneotherapy in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A Pilot Study of Hypnosis in the Treatment of Patients with Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

TNF polymorphisms in psoriasis: Association of psoriatic arthritis with the promoter polymorphismTNF*-857 independent of thePSORS1 risk allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2012.07919.X

10.1111/J.1610-0387.2012.07919.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

22386073

1 reference

9 May 2018